Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials.

Autor: Ribera JM; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Morgades M; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Genescà E; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Chapchap EC; Hematology Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Montesinos P; Hematology Department, Hospital Universitari i Politènic La Fe, Valencia, Spain., Acuña-Cruz E; Hematology Department, Hospital Universitari i Politènic La Fe, Valencia, Spain., Gil C; Hematology Department, Hospital General de Alicante, Alicante, Spain., García-Cadenas I; Hematology Department, Hospital de Sant Pau, Barcelona, Spain., Barba P; Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain., González-Campos J; Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Queipo de Llano MP; Hematology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Torrent A; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Ribera J; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Granada I; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Bernal T; Hematology Department, Hospital Central de Asturias, ISPA, IUOPA, Oviedo, Spain., Díaz-Beyá M; Hematology Department, Hospital Clínic, Barcelona, Spain., Amigo ML; Hematology Department, Hospital Morales Meseguer, Murcia, Spain., Coll R; Hematology Department, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain., Tormo M; Hematology and Oncology Department, Instituto de investigación INCLIVA, Hospital Clínico Universitario, Valencia, Spain., Vall-Llovera F; Hematology Department, Hospital Universitari Mútua de Terrasa, Terrassa, Spain., Gómez-Centurión I; Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Sánchez-Sánchez MJ; Hematology Department, Hospital Universitario Lucus Augusti, Lugo, Spain., Soria B; Hematology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Cladera A; Hematology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain., Artola MT; Hematology Department, Hospital Universitario de Donostia, Donostia, Spain., Garcia-Guiñon A; Hematology Department, Hospital Arnau de Vilanova, Lleida, Spain., Giménez-Conca A; Hematology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Amador ML; Hematology Department, Complejo Hospitalario de Pontevedra, Spain., Martínez-Sánchez P; Hematology Department, Hospital 12 de Octubre, Madrid, Spain., Algarra JL; Hematology Department, Hospital General Universitario Albacete, Albacete, Spain., Vidal MJ; Hematology Department, Hospital Universitario de León, León, Spain., Alonso N; Hematology Department, Hospital Universitario Santiago de Compostela, Santiago, Spain., Maluquer C; Hematology Department, Institut Catala d'Oncologia-Hospital Duran y Reynals, L'Hospitalet de Llobregat, Barcelona, Spain., Llorente L; Hematology Department, Hospital HM Sanchinarro, Madrid, Spain., García-Boyero R; Hematology Department, Hospital General Universitario de Castellón, Castellón, Spain., Ciudad J; Hematology Department, Centro de Investigación del Cáncer, IBSAL, IBMCC, CIBERONC, Hospital Universitario, Universidad de Salamanca-CSIC, Salamanca, Spain., Feliu E; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Orfao A; Hematology Department, Centro de Investigación del Cáncer, IBSAL, IBMCC, CIBERONC, Hospital Universitario, Universidad de Salamanca-CSIC, Salamanca, Spain.

Publikováno v: Hematological oncology [Hematol Oncol] 2021 Oct; Vol. 39 (4), pp. 529-538. Date of Electronic Publication: 2021 Aug 18.

Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.

Autor: Villaescusa T; Teresa Villaescusa de la Rosa. Hospital Virgen de la Concha. Avda. Requejo nº 35. 49022. Zamora. Spain. tvillaescusa@saludcastillayleon.es., Vázquez L, Bergua JM, García J, Romero A, Olave MT, García Belmonte D, Queipo de Llano MP

Publikováno v: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2020 Feb; Vol. 33 (1), pp. 44-48. Date of Electronic Publication: 2019 Dec 23.

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.

Autor: Guillem V; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain., Calabuig M; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain., Brunet S; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Esteve J; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain., Escoda L; d Department of Hematology , Hospital Universitari Joan XIII , Tarragona , Spain., Gallardo D; e Department of Hematology , ICO Girona, Hospital Josep Trueta, IDIBGI Foundation , Girona , Spain., Ribera JM; f Department of Hematology , ICO Badalona - Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona , Badalona , Spain., Queipo de Llano MP; g Department of Hematology , Hospital Virgen de la Victoria , Málaga , Spain., Arnan M; h Department of Hematology , ICO - Hospital Duran i Reynals , Barcelona , Spain., Pedro C; i Department of Hematology , Hospital del Mar, Parc de Salut Mar , Barcelona , Spain., Amigo ML; j Department of Hematology , Hospital Morales Meseguer , Murcia , Spain., Martí-Tutusaus JM; k Hospital Universitari Mútua Terrassa , Terrasa , Spain., García-Guiñón A; l Department of Hematology , Hospital Universitari Arnau de Villanova , Lleida , Spain., Bargay J; m Department of Hematology , Hospital Son Llatzer , Mallorca , Spain., Sampol A; n Department of Hematology , University Hospital Son Espases, Instituto IDISPA , Palma de Mallorca , Spain., Salamero O; o Department of Hematology , Hospital Vall d'Hebron , Barcelona , Spain., Font L; p Department of Hematology , Hospital Verge de la Cinta , Tortosa , Spain., Talarn C; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain., Hoyos M; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Díaz-Beyá M; c Department of Hematology , Hospital Clínic, IDIBAPS , Barcelona , Spain., Garrido A; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Navarro B; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain., Nomdédeu J; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Sierra J; b Department of Hematology , Hospital de Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institutes, Universidad Autónoma de Barcelona , Spain., Tormo M; a Department of Hematology and Medical Oncology , Hospital Clínico Universitario INCLIVA Biomedical Research Institute , Valencia , Spain.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2018 Oct; Vol. 59 (10), pp. 2383-2393. Date of Electronic Publication: 2018 Jan 18.

MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.

Autor: Díaz-Beyá M; 1] Hematology Department, Hospital Clinic, Institut d'Investigacions Bomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain [2] Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain., Brunet S; 1] Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain [2] Hematology Service, Institut d'Investigació Biomèdica Sant Pau. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Banc de Sang i Teixits de Catalunya, Spain., Nomdedéu J; 1] Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain [2] Laboratory of Hematology Service, Institut d'Investigació Biomèdica Sant Pau. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., Tejero R; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain., Díaz T; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain., Pratcorona M; 1] Hematology Department, Hospital Clinic, Institut d'Investigacions Bomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain [2] Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain., Tormo M; Hematology Department, Hospital Clínico, Valencia, Spain., Ribera JM; Hematology Department, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Spain., Escoda L; Hematology Department, Hospital Joan XXIII, Tarragona, Spain., Duarte R; Department of Hematology, Catalan Institute of Oncology (ICO), Hospital Duran i Reynals, Barcelona, Spain., Gallardo D; Hematology Department, Catalan Institute of Oncology (ICO), Girona, Spain., Heras I; Department of Hematology, University Hospital Morales Meseguer, Murcia, Spain., Queipo de Llano MP; Department of Hematology, Hospital Virgen de la Victoria, Málaga, Spain., Bargay J; Department of Hematology, Hospital de Son Llàtzer, Palma de Mallorca, Spain., Monzo M; Hematology Service, Institut d'Investigació Biomèdica Sant Pau. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Banc de Sang i Teixits de Catalunya, Spain., Sierra J; 1] Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain [2] Hematology Service, Institut d'Investigació Biomèdica Sant Pau. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Banc de Sang i Teixits de Catalunya, Spain., Navarro A; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain., Esteve J; 1] Hematology Department, Hospital Clinic, Institut d'Investigacions Bomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain [2] Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain.

Publikováno v: Leukemia [Leukemia] 2014 Apr; Vol. 28 (4), pp. 804-12. Date of Electronic Publication: 2013 Sep 27.

Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].

Autor: Perea G; Hematology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain., Lasa A, Aventín A, Domingo A, Villamor N, Queipo de Llano MP, Llorente A, Juncà J, Palacios C, Fernández C, Gallart M, Font L, Tormo M, Florensa L, Bargay J, Martí JM, Vivancos P, Torres P, Berlanga JJ, Badell I, Brunet S, Sierra J, Nomdedéu JF

Publikováno v: Leukemia [Leukemia] 2006 Jan; Vol. 20 (1), pp. 87-94.